Skip to main content
. 2013 Aug 7;6:657–664. doi: 10.2147/IJGM.S45880

Table 5.

BREEZE 3 changes noted in frequency and severity score of moderate or severe hot flashes from baseline at 4 weeks and 12 weeks relative to placebo

Doses 4 Weeks 12 Weeks
Frequency −1.69
(P < 0.0001)
−1.14
(P = 0.0007)
Severity −0.21
(P < 0.0001)
−0.19
(P = 0.0040)